Sign In
Buy BHVN
$10.81
+0.680 (+6.71%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
07:44pm, Tuesday, 04'th Mar 2025
NEW YORK , March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are advised to cont
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biohaven Ltd. (BHVN) And Encourages Stockholders to Connect
12:00pm, Tuesday, 04'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE:BHVN)
Strong Immunoglobulin Reduction Data Positions Biohaven's BHV-1300 As Potential Autoimmune Therapy
01:09pm, Monday, 03'rd Mar 2025
On Monday, Biohaven Ltd. BHVN highlighted data from BHV-1300, showing rapid and deep reductions in total IgG for the potential treatment of autoimmune disease.
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
07:31am, Monday, 03'rd Mar 2025
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody FcRn
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
07:30am, Monday, 03'rd Mar 2025
Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in all-genotype spinocerebellar ataxia; expected Pres
Biohaven's Exciting Year Of Catalysts
05:14am, Friday, 28'th Feb 2025
Following Pfizer's acquisition, Biohaven's valuation surged from $300M at $7/share to over $4B at $42/share under Vlad Coric's leadership. Despite the significant valuation increase, substantial upsid
Why Biohaven Stock Triumphed on Tuesday
06:42pm, Tuesday, 11'th Feb 2025
News of a big and important regulator's move was the electricity that powered Biohaven (BHVN 11.19%) stock to an 11%-plus gain on the second trading day of the week. Its leading investigational drug i
Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck
05:47pm, Tuesday, 11'th Feb 2025
Biohaven's NDA for Troriluzole in spinocerebellar ataxia was accepted by the FDA with Priority Review, potentially leading to approval in Q3 2025. BHV-7000, a selective Kv7 activator, is being studied
Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression on the pri
Presents progress and new anticipated milestones across portfolio of more than 10 assets and 6 therapeutic areas. Announces multiple advancements across the MoDETM (molecular degraders of extracellula
Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference
05:54pm, Tuesday, 07'th Jan 2025
NEW HAVEN, Conn. , Jan. 7, 2025 /PRNewswire/ -- Biohaven Ltd.
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval
02:23pm, Tuesday, 17'th Dec 2024
On Monday, Biohaven Ltd. BHVN revealed clinical and regulatory milestones across its proprietary Molecular Degrader of Extracellular Proteins (MoDE) platform and its glutamate modulation and ion chann
BHV-1300 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD. Subcutaneous BHV-1300 achieved rapid and progressive lowering of IgG within h
Reported expanded safety results from BHV-7000 Phase 1 multiple ascending dose studies, including the once-daily extended-release formulation being evaluated in ongoing Phase 2 and 3 clinical studies
